Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2012

View Archived Issues

Shionogi reports on first quarter of 2012

Synthetic Biologics to use Intrexon technology for mAb development

Genkyotex product attenuates liver fibrosis in vivo

University of Queensland researcher receives grant for nanoparticle delivery system

Novel computational method pairs known drugs with new uses

Researchers describe vaccine's cross-reactivity against Nipah virus

Abbott designs novel ALK blockers

Research at Actelion yields new S1P1 receptor agonists

Actinium and Philogen partner to develop adhesion-targeted anticancer radiotherapies

Dutch regulatory agency denies approval of Cortiment

New HDAC8/HDAC6 inhibitors patented

Salix and Alfa Wassermann enter agreement for EIR rifaximin formulation

FDA requests new validated test system for immunoglobulin preparation

McGill University presents new antibiotics

Topically delivered nanoparticle-siRNA conjugates suppress gene expression in vivo

Astellas and AstraZeneca gain approval in Japan for COPD therapeutic

Novel beta-secretase inhibitors created at Eisai

Japanese MHLW approves Bactramin/Baktar for additional indication

Humira approved for additional indication in Japan

Acquisition of Amylin Pharmaceuticals complete

AnaMar to conduct phase II studies of new analgesic and anti-inflammatory drug

Clovis Oncology launches CP-4126 combination trial

Galenea and CHDI Foundation extend and expand Huntington's disease collaboration

Nodality and Pfizer enter multiyear strategic collaboration

Sunitinib capsules approved in Japan for treatment of pancreatic neuroendocrine tumors

Japanese authorities grant new approval to ultrasound contrast agent

Flagyl approved for additional indication in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...